drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular immunotherapy (CAR T cells)
drug_description
Autologous gene-modified T-cell therapy expressing a bispecific CAR targeting BCMA (TNFRSF17) and GPRC5D; engagement triggers CD3ζ/costimulatory signaling, T-cell activation, and cytotoxic killing of malignant plasma cells, with dual targeting intended to reduce BCMA antigen escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a bispecific chimeric antigen receptor that recognizes BCMA (TNFRSF17) and GPRC5D on malignant plasma cells. Antigen binding triggers CAR CD3z and costimulatory signaling to activate and expand the T cells, leading to cytokine release and perforin/granzyme-mediated cytotoxic killing. Dual targeting is intended to reduce BCMA antigen escape and improve tumor clearance.
drug_name
BCMA–GPRC5D CAR-T cells
nct_id_drug_ref
NCT05998928